Verification of automated latex-enhanced particle immunoturbidimetric D-Dimer assays on different analytical platforms and comparability of test results.


Journal

Biochemia medica
ISSN: 1846-7482
Titre abrégé: Biochem Med (Zagreb)
Pays: Croatia
ID NLM: 9610305

Informations de publication

Date de publication:
15 Oct 2020
Historique:
received: 21 04 2020
accepted: 20 07 2020
entrez: 19 10 2020
pubmed: 20 10 2020
medline: 7 5 2021
Statut: ppublish

Résumé

The aim of the study was the analytical verification of automated latex-enhanced particle immunoturbidimetric (LPIA) D-Dimer assay INNOVANCE D-dimer on Sysmex CS-5100 and Atellica COAG 360 analysers, and HemosIL D-dimer HS500 on ACL TOP 550, as well as the comparison with the enzyme-linked immunofluorescent assay (ELFA) on the miniVidas analyser. Verification included assessment of within-run and between-run precision, bias, measurement uncertainty (MU), verification of the cut-off, method comparison between all assessed assays, and the reference commercial ELFA VIDAS D-Dimer Exclusion II. Within-run coefficients of variations (CVs) ranged from 1.6% (Atellica COAG 360) to 7.9% (ACL TOP 550), while between-run CVs ranged from 1.7% (Sysmex CS-5100) to 6.9% (Atellica COAG 360). Spearman's rank correlation coefficients were > 0.99 between LPIAs and ≥ 0.93 when comparing ELFA with LPIA. Passing-Bablok regression analysis yielded constant and proportional difference for comparison of ACL TOP 550 with both Sysmex CS-5100 and Atellica COAG360, and for miniVidas with Atellica COAG360. Small proportional difference was found between miniVidas and both Sysmex CS-5100 and ACL TOP 550. Calculated MUs using D-dimer HS 500 calibrator were 12.6% (Sysmex CS-5100) and 15.6% (Atellica COAG 360), while with INNOVANCE D-dimer calibrator 12.0% (Sysmex CS-5100), 10.0% (Atellica COAG 360) and 28.1% (ACL TOP 550). Excellent agreement of results was obtained, with occasional discrepancies near the cut-off. The cut-off (0.5 mg/L FEU) was confirmed. The obtained results prove satisfactory analytical performance of LPIAs, their high comparability and almost equal discriminatory characteristics, suggesting them as a valid alternative to ELFA.

Identifiants

pubmed: 33071556
doi: 10.11613/BM.2020.030705
pii: bm-30-3-030705
pmc: PMC7528643
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
Latex 0
Reagent Kits, Diagnostic 0
fibrin fragment D 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

030705

Informations de copyright

Croatian Society of Medical Biochemistry and Laboratory Medicine.

Déclaration de conflit d'intérêts

Potential conflict of interest None declared.

Références

Thromb Haemost. 2006 Mar;95(3):567-72
pubmed: 16525589
Clin Chem Lab Med. 2020 Jul 28;58(8):1191-1199
pubmed: 32432563
Thromb Res. 2016 Jan;137:219-220
pubmed: 26620264
BMJ. 2013 May 03;346:f2492
pubmed: 23645857
Ann Clin Lab Sci. 2011 Fall;41(1):20-4
pubmed: 21325250
Clin Chem Lab Med. 2009;47(8):945-51
pubmed: 19548843
Crit Rev Clin Lab Sci. 2018 Dec;55(8):548-577
pubmed: 30694079
Clin Chem. 1996 Mar;42(3):410-5
pubmed: 8598104
J Thromb Thrombolysis. 2015 Jan;39(1):55-9
pubmed: 25006010
Thromb Res. 2010 May;125(5):398-401
pubmed: 19683797
Lab Med. 2016 May;47(2):90-102
pubmed: 27016528
Clin Chem. 2011 Sep;57(9):1256-62
pubmed: 21719689
J Am Coll Cardiol. 2017 Nov 7;70(19):2411-2420
pubmed: 29096812
Int J Lab Hematol. 2017 May;39 Suppl 1:98-103
pubmed: 28447414
Semin Thromb Hemost. 2015 Apr;41(3):287-93
pubmed: 25839870
Clin Chem Lab Med. 2016 Feb;54(2):235-9
pubmed: 26540227
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
Thromb Res. 2013;132(6):676-80
pubmed: 24139507
Blood Coagul Fibrinolysis. 2008 Dec;19(8):817-21
pubmed: 19002050
J Clin Lab Anal. 2019 Feb;33(2):e22687
pubmed: 30320416

Auteurs

Ivana Lapić (I)

Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.

Désirée Coen Herak (D)

Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.

Snježana Prpić (S)

Medical Biochemistry Laboratory Dunja Horvat, Primary Care Center Sisak, Sisak, Croatia.

Andrea Prce (A)

Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.

Vanja Raščanec (V)

Medical Biochemistry Laboratory, General Hospital "Dr. Tomislav Bardek", Koprivnica, Croatia.

Renata Zadro (R)

Medical Biochemistry Laboratory, St Catherine Specialty Hospital, Zagreb, Croatia.

Dunja Rogić (D)

Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH